Antiaggregant activity of a new benzimidazole derivative.
Antiaggregant activity of a new tricyclic benzimidazole derivative, RU-891 compound, was studied on the model of ADP-induced platelet aggregation in vitro and intravascular platelet aggregation in vivo. We evaluated the effect of this substance on blood coagulation potential. Antiaggregant agent acetylsalicylic acid was used as the reference drug. RU-891 produced a dose-dependent antiaggregant effect in vivo and in vitro that exceeded the effect of the reference drug. This compound did not modulate blood coagulation potential.
Department of Pharmacology, Volgograd State Medical University, Volgograd, Russia, aidakucheryzvenko@yandex.ru.
A F
AF
Kucheryavenko
A A
AA
Spasov
V I
VI
Petrov
V A
VA
Anisimova
D000818:Animals; D001241:Aspirin; D001562:Benzimidazoles / Q000494:pharmacology* / Q000633:toxicity; D001777:Blood Coagulation / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D007928:Lethal Dose 50; D010974:Platelet Aggregation / Q000187:drug effects*; D011817:Rabbits; D051381:Rats; D018709:Statistics, Nonparametric
C583978:9-(2-(3,4-dihydroxydiphenyl)-2-oxoethyl)-2,3-dihydroimidazo(1,2-a)benzimidazole; D001562:Benzimidazoles; D001241:Aspirin